<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055405</url>
  </required_header>
  <id_info>
    <org_study_id>JA Barbera</org_study_id>
    <nct_id>NCT01055405</nct_id>
  </id_info>
  <brief_title>Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension</brief_title>
  <acronym>SIL-COPD-02</acronym>
  <official_title>Phase IV Study on the Effects of Sildenafil in Combination With Pulmonary Rehabilitation Program on Exercise Tolerance in Patients With COPD and Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sildenafil is a phosphodiesterase-5 inhibitor that has been approved for the treatment of
      pulmonary arterial hypertension with orphan drug designation. Sildenafil modulates the nitric
      oxide (NO) pathway in the vessel wall. Since this pathway is impaired in pulmonary arteries
      of patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary
      disease (COPD), the investigators hypothesized that sildenafil might improve pulmonary
      hemodynamics and increase exercise tolerance in this condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, randomized, double-blind, placebo controlled trial to assess the effect
      of 3 months treatment with sildenafil (20 mg/8 h), added to a pulmonary rehabilitation
      program, on exercise tolerance. Subjects: 60 patients (30 by treatment group). Main end-point
      variable: endurance time in constant work exercise test (CWET). Other measurements: 6 min
      walk distance, performance in incremental exercise test, physiological and metabolic response
      at iso-time and iso-load in CWET, dyspnea, and health-related quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 min walk distance, performance in incremental exercise test, physiological and metabolic response at iso-time and iso-load in CWET, dyspnea, and health-related quality of life</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>COPD</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Sildenafil plus pulmonary rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus pulmonary rehabilitation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 20mg TID orally</description>
    <arm_group_label>Sildenafil plus pulmonary rehabilitation</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo TID orally</description>
    <arm_group_label>Placebo plus pulmonary rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD, FEV1 &lt; 80% ref. and FEV1/FVC &lt; 0.7 post bronchodilator

          -  Age 40-80 years

          -  Pulmonary hypertension

          -  Consent to participate in the study

        Exclusion Criteria:

          -  Pulmonary or extrapulmonary disease that modifies gas exchange or pulmonary
             hemodynamics

          -  Recent exacerbation (&lt;4 weeks) (temporally)

          -  Patients treated with nitrates or CYP3A4 inhibitors (ketoconazole, itraconazole,
             ritonavir)

          -  Ischemic optic neuropathy

          -  Patients treated with phosphodiesterase-5 inhibitors

          -  Patients with ischemic cardiopathy

          -  Systemic disease that could modified the results

          -  Patients unable to practise exercise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Albert Barbera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Joan Albert Barbera Mir</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Exercise tolerance</keyword>
  <keyword>COPD</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

